Revvity Signals Software has unveiled Signals One, a comprehensive platform designed to integrate data management across the entire drug discovery process. The unified system supports the complete ‘Design-Make-Test-Decide’ research and development lifecycle, with advanced capabilities aimed at tackling previously ‘undruggable’ targets through standardised, AI-ready data workflows.
Azenta Life Sciences has introduced the IntelliXcap™ S1, a versatile single tube decapper/recapper designed to simplify handling of large-format tubes (11-40mm) in laboratory settings. This adaptable system eliminates manual adjustments typically required when working with different tube types, offering significant workflow improvements for both low and high-throughput laboratories.
VectorY Therapeutics, an emerging biotechnology company focused on vectorized antibody therapies for neurodegenerative diseases, has appointed Dr. Olga Uspenskaya-Cadoz as Chief Medical Officer (CMO). The strategic appointment comes at a pivotal moment as the company prepares to submit an Investigational New Drug (IND) application for its lead candidate, VTx-002, for sporadic amyotrophic lateral sclerosis (ALS) […]
Revvity, Inc. has significantly expanded its collaboration with Genomics England to provide comprehensive genomic screening services for newborns in England. The new agreement builds upon an existing partnership by adding DNA sequencing services to Revvity’s current DNA extraction capabilities.
Bio-Rad Laboratories has achieved a significant regulatory milestone with EU Quality Management Systems certification under the In Vitro Diagnostic Regulation (IVDR), enabling CE marking for 40 infectious disease molecular quality control products from their Exact Diagnostics brand.
FairJourney Biologics S.A., a global leader in antibody discovery and development based in Porto, Portugal, has announced the formation of a new Supervisory Board aimed at enhancing the company’s strategic positioning and accelerating innovation in antibody research. The board, comprising distinguished industry veterans with extensive expertise in biopharmaceutical development, will focus on defining key growth […]
The equity-free accelerator programme, based in Basel’s life sciences hub, aims to address the 80% failure rate of healthtech startups by providing direct access to pharmaceutical expertise and resources.
Cancer diagnostics in Germany is set to enter a new phase as Labor Dr. Wisplinghoff collaborates with US-based Genomic Testing Cooperative to implement advanced molecular testing capabilities, with RNA analysis at the forefront of this precision medicine initiative.
German biotechnology company Navigo Proteins has established a strategic research collaboration with SCK CEN, the Belgian Nuclear Research Centre, to accelerate development of targeted radiotheranostics. The partnership aims to combine Navigo’s expertise in precision carrier molecules with SCK CEN’s capabilities in radioisotope production and preclinical testing.
Wiley has announced the release of its 2025 edition of the Mass Spectra of Designer Drugs database, a critical resource expanding forensic laboratories’ capabilities in the identification of illicit substances. The updated database represents a substantial advancement in analytical tools available to forensic scientists combating the proliferation of novel psychoactive substances.
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
